Wipfli Financial Advisors’s Celldex Therapeutics CLDX Stock Holding History

Wipfli Financial Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$4K	Buy	+131	New	+$4.02K	﹤0.01%	2130

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wipfli Financial Advisors's CLDX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Celldex Therapeutics (CLDX) in Q3 2022: 131 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #2130 among its holdings.

159 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

Wipfli Financial Advisors held 131 shares of Celldex Therapeutics worth $4K as of Q3 2022.
Celldex Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
Celldex Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2130 holding.
159 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.